Cell technologies in retinitis pigmentosa treatment

2022

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.23950/jcmk/11931
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

The growing crucial problem in practical ophthalmology relates to growth of hereditary degenerative diseases of the retina, in particular retinitis, causing progressive loss of visual functions. According to international estimates, the incidence rate of hereditary dystrophy contains 1 case per 3000 population. With the development of biomedical cell technologies, transplantation of stem (autologous and allogeneic) cells is at the stage of active research. The article reviewed literature sources on prevalence, risk factors, etiopathogenesis, diagnosis, clinical picture and treatment of retinitis pigmentosa.